$2.67 Billion is the total value of BVF INC/IL's 67 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 36.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $238,778,000 | +1251.5% | 6,338,678 | +510.3% | 8.95% | +1188.1% |
| OLMA | OLEMA PHARMACEUTICALS INC | $221,029,000 | -31.0% | 6,661,503 | 0.0% | 8.29% | -34.2% | |
| MRUS | Buy | MERUS N V | $152,185,000 | +49.5% | 7,285,071 | +25.5% | 5.71% | +42.5% |
| XOMA | Sell | XOMA CORP DEL | $144,081,000 | -21.9% | 3,530,543 | -15.6% | 5.40% | -25.6% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $135,027,000 | +23.2% | 2,943,049 | +6.3% | 5.06% | +17.4% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $114,240,000 | +12.1% | 3,722,398 | +25.2% | 4.28% | +6.8% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $102,550,000 | +19.0% | 3,959,451 | -7.4% | 3.84% | +13.5% |
| KYMR | KYMERA THERAPEUTICS INC | $102,227,000 | -37.3% | 2,630,658 | 0.0% | 3.83% | -40.3% | |
| RLAY | Sell | RELAY THERAPEUTICS INC | $99,325,000 | -22.2% | 2,873,147 | -6.5% | 3.72% | -25.9% |
| ARGX | Buy | ARGENX SEsponsored adr | $85,260,000 | +363.9% | 309,599 | +395.4% | 3.20% | +342.2% |
| EPIX | Sell | ESSA PHARMA INC | $84,487,000 | +91.1% | 2,908,326 | -21.5% | 3.17% | +82.2% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $62,324,000 | +15.8% | 3,481,778 | -0.5% | 2.34% | +10.4% |
| IONS | IONIS PHARMACEUTICALS INC | $61,346,000 | -20.5% | 1,364,461 | 0.0% | 2.30% | -24.2% | |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $61,287,000 | +35.7% | 2,607,969 | -19.2% | 2.30% | +29.3% |
| ACIU | Sell | AC IMMUNE SA | $57,110,000 | +12.5% | 7,504,579 | -23.6% | 2.14% | +7.2% |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $52,682,000 | -26.3% | 1,876,122 | -31.8% | 1.98% | -29.7% |
| LXRX | Sell | LEXICON PHARMACEUTICALS INC | $49,273,000 | +31.4% | 8,394,000 | -23.4% | 1.85% | +25.2% |
| KURA | Buy | KURA ONCOLOGY INC | $46,225,000 | +13.6% | 1,635,112 | +31.2% | 1.73% | +8.2% |
| IKNA | New | IKENA ONCOLOGY INC | $45,190,000 | – | 1,599,658 | +100.0% | 1.69% | – |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $44,728,000 | -2.4% | 1,031,070 | -6.8% | 1.68% | -7.0% |
| CGEM | New | CULLINAN ONCOLOGY INC | $43,727,000 | – | 1,049,356 | +100.0% | 1.64% | – |
| CTMX | CYTOMX THERAPEUTICS INC | $43,106,000 | +18.0% | 5,576,471 | 0.0% | 1.62% | +12.5% | |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $36,147,000 | +79.1% | 2,864,299 | +33.3% | 1.36% | +70.7% |
| SPRO | Sell | SPERO THERAPEUTICS INC | $31,471,000 | -27.6% | 2,137,978 | -4.7% | 1.18% | -31.0% |
| GLYC | GLYCOMIMETICS INC | $28,728,000 | -19.9% | 9,544,262 | 0.0% | 1.08% | -23.7% | |
| VIRX | New | VIRACTA THERAPEUTICS INC | $28,621,000 | – | 3,094,174 | +100.0% | 1.07% | – |
| VSTM | Buy | VERASTEM INC | $28,358,000 | +19.1% | 11,480,994 | +2.7% | 1.06% | +13.4% |
| INFI | Sell | INFINITY PHARMACEUTICALS INC | $27,079,000 | -26.7% | 8,383,645 | -51.9% | 1.02% | -30.1% |
| OVID | Buy | OVID THERAPEUTICS INC | $25,799,000 | +147.0% | 6,417,551 | +41.9% | 0.97% | +135.3% |
| ANAB | New | ANAPTYSBIO INC | $25,634,000 | – | 1,189,500 | +100.0% | 0.96% | – |
| FBRX | FORTE BIOSCIENCES INC | $24,633,000 | -5.9% | 718,788 | 0.0% | 0.92% | -10.3% | |
| CALT | CALLIDITAS THERAPEUTICS ABsponsered ads | $20,723,000 | -18.7% | 750,000 | 0.0% | 0.78% | -22.5% | |
| CTIC | CTI BIOPHARMA CORP | $20,165,000 | -9.6% | 6,929,690 | 0.0% | 0.76% | -13.9% | |
| STRO | Sell | SUTRO BIOPHARMA INC | $18,819,000 | -53.2% | 826,825 | -55.4% | 0.71% | -55.4% |
| IMVT | Buy | IMMUNOVANT INC | $18,350,000 | -22.8% | 1,144,016 | +122.4% | 0.69% | -26.4% |
| CFRX | Buy | CONTRAFECT CORP | $18,299,000 | +126.5% | 3,812,300 | +138.3% | 0.69% | +115.7% |
| GRTS | Sell | GRITSTONE ONCOLOGY INC | $17,551,000 | +65.3% | 1,861,239 | -30.9% | 0.66% | +57.4% |
| SLN | New | SILENCE THERAPEUTICS PLCads | $15,820,000 | – | 666,666 | +100.0% | 0.59% | – |
| ANGN | New | ANGION BIOMEDICA CORP | $15,811,000 | – | 875,000 | +100.0% | 0.59% | – |
| PIRS | PIERIS PHARMACEUTICALS INC | $14,121,000 | +2.8% | 5,494,582 | 0.0% | 0.53% | -2.0% | |
| REPL | New | REPLIMUNE GROUP INC | $14,078,000 | – | 461,428 | +100.0% | 0.53% | – |
| CALA | Buy | CALITHERA BIOSCIENCES INC | $13,471,000 | -37.1% | 5,566,690 | +27.6% | 0.50% | -40.0% |
| COGT | UNUM THERAPEUTICS INC | $13,453,000 | -21.8% | 1,532,282 | 0.0% | 0.50% | -25.6% | |
| MEIP | Sell | MEI PHARMA INC | $12,307,000 | +15.1% | 3,588,155 | -11.4% | 0.46% | +9.5% |
| ELDN | New | ELEDON PHARMACEUTICALS INC | $11,914,000 | – | 1,113,435 | +100.0% | 0.45% | – |
| GNCA | GENOCEA BIOSCIENCES INC | $10,874,000 | +12.0% | 4,012,404 | 0.0% | 0.41% | +6.8% | |
| SELB | Sell | SELECTA BIOSCIENCES INC | $10,769,000 | +7.5% | 2,379,986 | -28.0% | 0.40% | +2.5% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $10,656,000 | -79.8% | 1,715,981 | -84.1% | 0.40% | -80.7% |
| CDTX | CIDARA THERAPEUTICS INC | $9,948,000 | +33.0% | 3,739,704 | 0.0% | 0.37% | +26.9% | |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $9,947,000 | +43.7% | 3,229,426 | +66.1% | 0.37% | +37.1% |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $9,398,000 | +84.3% | 1,091,579 | +37.7% | 0.35% | +75.1% |
| BCTG | BCTG ACQUISITION CORP | $8,896,000 | -2.8% | 800,000 | 0.0% | 0.33% | -7.2% | |
| RACA | Sell | THERAPEUTICS ACQUISITION COR | $8,116,000 | -39.1% | 772,226 | -19.1% | 0.30% | -42.0% |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $7,745,000 | – | 463,504 | +100.0% | 0.29% | – |
| ALRN | New | AILERON THERAPEUTICS INC | $7,530,000 | – | 5,265,555 | +100.0% | 0.28% | – |
| GLMD | GALMED PHARMACEUTICALS LTD | $6,173,000 | +10.3% | 1,799,694 | 0.0% | 0.23% | +5.0% | |
| RACB | New | RESEARCH ALLIANCE CORP II | $5,125,000 | – | 500,000 | +100.0% | 0.19% | – |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $5,105,000 | -1.9% | 500,000 | 0.0% | 0.19% | -6.8% | |
| EUCRU | EUCRATES BIOMEDICAL ACQU CORunit 10/23/2027 | $5,030,000 | -5.6% | 500,000 | 0.0% | 0.19% | -10.0% | |
| FVAM | 5 01 ACQUISITION CORP | $4,975,000 | -2.2% | 500,000 | 0.0% | 0.19% | -6.5% | |
| ERYP | ERYTECH PHARMAsponsored adr | $4,469,000 | -27.0% | 625,000 | 0.0% | 0.17% | -30.3% | |
| FWP | FORWARD PHARMA A/Ssponsord ads new | $4,434,000 | -2.7% | 647,299 | 0.0% | 0.17% | -7.3% | |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $3,656,000 | -81.3% | 163,524 | -81.4% | 0.14% | -82.2% |
| JYAC | JIYA ACQUISITION CORP | $2,952,000 | -4.5% | 300,000 | 0.0% | 0.11% | -9.0% | |
| IVA | New | INVENTIVA SAads | $1,573,000 | – | 107,000 | +100.0% | 0.06% | – |
| RZLT | Buy | REZOLUTE INC | $1,347,000 | -42.9% | 190,815 | +0.0% | 0.05% | -45.2% |
| LSAQ | LIFESCI ACQUISITION II CORP | $1,014,000 | -4.5% | 100,000 | 0.0% | 0.04% | -9.5% | |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -50 | -100.0% | 0.00% | – |
| PANAU | Exit | PANACEA ACQUISITION CORPunit 99/99/9999 | $0 | – | -9,837 | -100.0% | -0.01% | – |
| MGEN | Exit | MIRAGEN THERAPEUTICS INC | $0 | – | -9,747 | -100.0% | -0.01% | – |
| FSTX | Exit | F-STAR THERAPEUTICS INC | $0 | – | -25,844 | -100.0% | -0.01% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -1,727,308 | -100.0% | -0.14% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -3,376,207 | -100.0% | -0.18% | – |
| PHAT | Exit | PHATHOM PHARMACEUTICALS INC | $0 | – | -150,787 | -100.0% | -0.20% | – |
| CRIS | Exit | CURIS INC | $0 | – | -626,945 | -100.0% | -0.20% | – |
| GMDA | Exit | GAMIDA CELL LTD | $0 | – | -1,343,667 | -100.0% | -0.44% | – |
| NVUS | Exit | NOVUS THERAPEUTICS INC | $0 | – | -763,279 | -100.0% | -0.46% | – |
| ALXO | Exit | ALX ONCOLOGY HLDGS INC | $0 | – | -540,837 | -100.0% | -1.83% | – |
| XNCR | Exit | XENCOR INC | $0 | – | -1,264,754 | -100.0% | -2.17% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -4,878,035 | -100.0% | -3.99% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.